Breaking Finance News

Lion Biotechnologies Inc (NASDAQ:LBIO) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.

Zacks Investment Research has upgraded Lion Biotechnologies Inc (NASDAQ:LBIO) to Hold in a statement released on 5/23/2017.

On 5/10/2017, Rodman & Renshaw released a statement for Lion Biotechnologies Inc (NASDAQ:LBIO) bumped up the target price from $0.00 to $13.00 that suggested an upside of 1.15%.

Boasting a price of $6.40, Lion Biotechnologies Inc (NASDAQ:LBIO) traded -4.92% lower on the day. With the last stock price close down -16.77% from the two hundred day average, compared with the S&P 500 Index which has increased 0.01% over the date range. Lion Biotechnologies Inc has recorded a 50-day average of $6.45 and a two hundred day average of $6.97. Volume of trade was up over the average, with 528,308 shares of LBIO changing hands over the typical 260,573

Performance Chart

Lion Biotechnologies Inc (NASDAQ:LBIO)

With a total market value of $0, Lion Biotechnologies Inc has with a one year low of $5.12 and a one year high of $9.58 .

Brief Synopsis About Lion Biotechnologies Inc (NASDAQ:LBIO)

Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.